ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,975,827 | +4.9% | 170,609 | 0.0% | 1.19% | +14.6% |
| Q2 2023 | $15,226,853 | -43.5% | 170,609 | -32.1% | 1.04% | -49.2% |
| Q1 2023 | $26,953,714 | +33.0% | 251,387 | +51.5% | 2.05% | +15.4% |
| Q4 2022 | $20,265,886 | +42.7% | 165,937 | +20.6% | 1.78% | +34.9% |
| Q3 2022 | $14,204,000 | +42.9% | 137,554 | +28.6% | 1.32% | +40.3% |
| Q2 2022 | $9,940,000 | -54.8% | 106,931 | -42.9% | 0.94% | -40.0% |
| Q1 2022 | $21,993,000 | +45.8% | 187,401 | +67.1% | 1.56% | +63.9% |
| Q4 2021 | $15,084,000 | +248.8% | 112,122 | +313.2% | 0.96% | +202.2% |
| Q3 2021 | $4,325,000 | +692.1% | 27,134 | +484.4% | 0.32% | +544.9% |
| Q1 2019 | $546,000 | – | 4,643 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |